AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Other Neuroscience by Quarter
Other Neuroscience — International operational (constant-currency) growth YoY (%) (%)
AbbVie Other Neuroscience: -12.4% in Q2 2026, up 8.9 pts from a year earlier.
Latest, Q2 2026
-12.4%
Period ended Jun 30, 2026
Change on a year earlier
+8.9 pts
-21.3% in Q2 2025
History
16 quarters
Since Q3 2021
Sources
16
Documents cited below
Where the Q2 2026 figure comes from
“|| Other Neuroscience | 43 | 74 | 117 | (38.6) | (8.9) | (22.7) | (12.4) | (24.6)”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Other Neuroscience (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/other-neuro-intl-op-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.